VORAXAZE
Peakglucarpidase
BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VORAXAZE (glucarpidase) is a recombinant carboxypeptidase enzyme administered by injection that rapidly inactivates methotrexate and its metabolites. It is indicated for patients experiencing delayed methotrexate clearance (high-dose methotrexate toxicity) following cancer chemotherapy. The drug works by enzymatically cleaving terminal glutamate residues from methotrexate, converting it to inactive metabolites that can be more readily eliminated.
Peak
Product is at peak maturity with moderate competitive pressure (30); team focus likely on maintaining market position and managing institutional relationships.
Mechanism of Action
Pharmacologic Class:
Carboxypeptidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
Started Mar 2019
11 enrolled
Osteosarcoma
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Started Jul 2008
47 enrolled
Acute Lymphoblastic Leukemia (ALL)
Career Relevance
Working on VORAXAZE means supporting a specialized, niche oncology product with a loyal but limited patient base. Career growth depends on managing market access, building institutional relationships, and potentially exploring label expansion or new formulations.
Medical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.